JS107

DRUG2 trials

Sponsors

Shanghai Junshi Bioscience Co., Ltd.

Conditions

Advanced Pancreatic CancerAdvanced Solid Tumors

Phase 1

A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors

Active, not recruitingNCT05502393

Shanghai Junshi Bioscience Co., Ltd.Advanced Solid Tumors

Start: 2022-07-26End: 2027-12-31Updated: 2026-08-07

A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer

TerminatedNCT05657418

Shanghai Junshi Bioscience Co., Ltd.Advanced Pancreatic Cancer

Start: 2022-03-29End: 2025-01-04Updated: 2025-06-06

Related Papers

Abstract CT010: Phase I dose-escalation and expansion study of JS107, a claudin 18.2 (CLDN18.2)-targeting antibody-drug conjugate (ADC), as monotherapy or in combination for patients (pts) with advanced solid tumors

Cancer Research2025-04-251 citations